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264Objectives: The Edwards Prima Plus was one of the first stentless aortic valve bioprostheses, with larger orifice
areas and improved hemodynamics compared to stented bioprostheses. The aim of the present single-center
retrospective studywas to assess the long-term results of theEdwards PrimaPlus in patients 60years old or younger.
Methods: From 1993 to 2001, 120 patients (99 men and 21 women) aged 60 years or younger underwent
implantation of the Edwards Prima Plus. The indications were stenosis and/or insufficiency. Associated proce-
dures were performed in 38 patients (31.7%). Of the patients, 39% had impaired left ventricular function.
Follow-up data were acquired by telephone interview. Time-to event analyses were performed using the
Kaplan-Meier method. Variables affecting survival and freedom from reoperation were evaluated using Cox re-
gression analysis. The mean patient age at surgery was 53.1  8.0 years. The follow-up data were 88.8% com-
plete at a mean of 8.5  4.5 years. The total follow-up was 1022.7 patient-years.
Results: At 10 and 15 years, the overall actuarial survival rate was 71.8% 4.4% and 48.8% 9.6%, respec-
tively. Survival was significantly lower for patients with older age, aortic insufficiency as the surgical indication,
and small prosthesis size (25 mm vs27 mm). Reoperation was performed in 20 patients (16.7%), with a hos-
pital mortality of 5%. At 10 and 14 years, the overall freedom from reoperation rate was 85.6%  3.7% and
65.2%  8.6%, respectively. Freedom from reoperation was significantly lower in patients with a small pros-
thesis size (25 mm) and insufficiency as the indication for surgery.
Conclusions: In patients aged 60 years or younger, an Edwards Prima Plus can provide reliable long-term results
with acceptable freedom-from-reoperation rates. (J Thorac Cardiovasc Surg 2014;147:264-9)The Edwards Prima Plus (EPP) was introduced in the early
1990s. It is one of the first stentless aortic valves (SAVs).
The SAVs have larger orifice areas and lower transvalvular
pressure gradients than the stented aortic valve replace-
ments (AVRs) owing to improved hemodynamics.1 Re-
duced calcification in the murine model could be shown
for the preservation method used for the EPP.2 Furthermore,
the clinical midterm results also revealed excellent freedom
from structural valve deterioration.3
The actual guidelines recommend mechanical AVR in
patients aged 60 years or younger and bioprosthetic AVR
in patients older than 60 years.4 This is because of the
greater durability of mechanical AVR, which circumvents
the need for later reoperations. However, no significant dif-
ference exists in survival between mechanical and biopros-
thetic AVR.5 EPP could have better longevity and therefore
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The Journal of Thoracic and Cardiovascular Surgdemonstrated advanced hemodynamics and a reduced
potential for calcification. The aim of the present single-
center retrospective study was to assess the long-term re-
sults after implantation of an EPP in patients aged 60 years
or younger to determine whether the age recommendation
in guidelines can be lowered for implantation of EPPs.METHODS
From 1993 to 2001, 120 consecutive patients aged 60 years or younger
underwent implantation of an EPP. Either the patient’s explicit desire for
a bioprosthetic AVR or a contraindication to oral anticoagulation resulted
in the choice of an EPP. During the study period, 321 patients aged 60
years or younger underwent implantation of a mechanical prosthesis in
the aortic position. The indications were stenosis and/or regurgitation. Pa-
tients with endocarditis and dissections of the ascending aorta were
excluded.
Follow-up data were acquired through telephone interviews and/or
clinical examination and follow-up was closed on October 21, 2010.
The follow-up data were 88.8% complete at a mean of 8.5  4.5 years.
The total follow-up period was 1022.7 patient-years, with a maximum of
17.0 years.
Data collection and statistical analyses were done according to the cur-
rent guidelines for reporting mortality and morbidity after cardiac valve in-
terventions.6 The local ethics committee approved the study.
Statistical Analysis
All data were analyzed with PASW Statistics, version 18.0.0 (SPSS,
Chicago, Ill). Descriptive statistics are reported as the mean  standard
deviation for continuous variables and as frequencies and percentagesery c January 2014
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
EPP ¼ Edwards Prima Plus
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event analyses were performed using Kaplan-Meier actuarial methods.
Age-stratified curve comparisons were performed using the log-rank
test. All P values were 2-sided. In addition, proportional hazard models
were used to investigate the following variables as risk factors for sur-
vival and freedom from reoperation: gender, age, left ventricular function,
aortic valve lesion, associated procedures, and EPP diameter. The preop-
erative characteristics often associated with mortality (eg, renal function,
diabetes, chronic obstructive lung disease, peripheral arterial disease, pul-
monary hypertension) were not adequately captured during the earlier
portion of the study. In the later portion of the study, these characteristics
were not often present (probably because of the low age of the study co-
hort). Thus, these characteristics were not entered as covariates in the
analyses.
Age- and gender-matched survival estimates from the German general
population were obtained from the Human Life Table Database.7 Age-
and gender-specific conditional probabilities of surviving a 1-year age in-
terval were used to create an age- and gender-matched patient sample. The
survival line depicted in Figure 1 represents these averaged conditional
probabilities of survival.
RESULTS
The baseline preoperative characteristics and operative
data are presented in Table 1.
Overall, the hospital mortality was 3.3% (n ¼ 4). At 10
and 15 years, the overall actuarial survival rate was
71.8%  4.4% and 48.8%  9.6%, respectivelyFIGURE 1. Survival of study population compared with general population a
cedure, and stenotic valve lesion. EPP, Edwards Prima Plus.
The Journal of Thoracic and Ca(Figure 1). For isolated implantation of an EPP, the actu-
arial survival at 10 and 15 years was 69.5%  5.5% and
62.5%  8.2%. The linearized mortality rate was 3.3%/y
overall and 3.0%/y for isolated implantation of an EPP.
On univariate risk stratification, older age, isolated insuf-
ficiency as the surgical indication, and small prosthesis
size (EPP 25 mm vs 27 mm) significantly lowered
survival. Multivariate risk stratification supported these
risk factors (Table 2).
Overall, reoperation was performed in 20 patients: in 17
because of structural valve deterioration and in 3 because
of endocarditis. At 10 and 14 years, the overall freedom
from reoperation rate was 85.6%  3.7% and
65.2%  8.6%, respectively (Figure 2). Only 1 patient was
at risk at 15 years for determining the freedom from reopera-
tion rate and 3 patients were for determining the 14-year free-
dom from reoperation rate. Therefore, the later reoperation
rates should be considered with caution, and additional
follow-up is needed. Univariate and multivariate risk stratifi-
cation revealed small prosthesis size (EPP 25 mm vs 27
mm) and isolated insufficiency as the surgical indication
as predictors of inferior freedom-from-reoperation rates
(Table 2).
The hospital mortality of patients after reoperation was
5% (n ¼ 1) and, in consideration of the low number of
cases, comparable to the overall hospital mortality.DISCUSSION
The use of biologicAVR inyounger patients is still contro-
versial. Themajor disadvantage of biologicAVR is structuralnd patients with normal left ventricular function, isolated aortic valve pro-
rdiovascular Surgery c Volume 147, Number 1 265
TABLE 1. Baseline characteristics and operative data
Characteristic Value
Patients 120
Mean age (y) 53.1  8.0
Gender
Male 99 (82.5)
Female 21 (17.5)
Aortic valve lesion
Stenosis 38 (31.7)
Insufficiency 51 (42.5)
Mixed lesion 31 (25.8)
Left ventricular function
Normal (LVEF>50%) 73 (61)
Moderately impaired (LVEF<50% but>30%) 33 (27)
Profoundly impaired (LVEF<30%) 14 (12)
Isolated EPP implantation 82 (68.3)
Combined procedure 38 (31.7)
Implanted valve size (mm)
23 1 (0.8)
25 22 (18.3)
27 50 (41.7)
29 47 (29.2)
Data in parentheses are percentages. EPP, Edwards Prima Plus; LVEF, left ventricular
ejection fraction.
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2006, the American Heart Association and the American
College ofCardiology recommended the use of bioprosthetic
AVR in patients older than 65 years.8,9 An update in 2010
lowered the age to 60 years4 because of improved valve du-
rability and lowered risk of reoperation, even with the in-
creasing life expectancy. The EPP, as a representative of
SAVs, shows better hemodynamic performance than
a stented AVR.1 In patients with left ventricular impairment,
implantation of SAVs results in greater improvement of left
ventricular function10 and a reduction of late mortality is
shown.11 Additionally, there could be an effect on long-
term durability, owing to less stress on the bioprosthetic
cusps caused by a more physiologic flow pattern.
Various studies have reported on the mortality and dura-
bility after AVR, but only few were primarily concernedTABLE 2. Risk factors for survival and freedom from reoperation in
multivariate analysis
Characteristic
Survival
Freedom from
reoperation
OR 95% CI
P
value OR 95% CI
P
value
Age 1.07 1.01-1.14 .04 0.96 0.97-0.92 .22
Gender 1.68 0.56-5.04 .35 4.05 0.94-17.5 .06
Aortic valve lesion 5.17 1.38-15.64 .01 0.25 0.09-0.71 .01
Left ventricular function 0.46 0.17-1.21 .11 1.68 0.6-4.7 .33
Associated procedures 1.44 0.68-3.04 .34 1.68 0.57-4.95 .34
Diameter of EPP
(25 mm)
3.06 1.49-6.3 .00 6.36 2.26-17.87 .00
OR, Odds ratio; CI, confidence interval; EPP, Edwards Prima Plus.
266 The Journal of Thoracic and Cardiovascular Surgwith the long-term results in younger patients. For example,
Weber and colleagues12 recently published a comparison of
stented pericardial tissue valves and mechanical prostheses
for AVR in patients younger than 60 years old. They re-
ported a reduced midterm survival after implantation of
stented pericardial tissue valves; however, they had
a mean follow-up of just 33 months. In particular, for
SAVs, owing to their introduction only about 20 years
ago, only few long-term results have been published for
larger cohorts of patients aged 60 years old. For example,
Bach and colleagues13 reported excellent clinical outcomes
and durability for the Medtronic Freestyle prosthesis (Med-
tronic, Minneapolis, Minn), although they reported on only
about 57 patients with a mean follow-up of just 6.8 years.
For the EPP, no long-term results for patients aged 60 years
or younger have been published. The longest published
follow-up has been for patients with a mean age of 72.2
years.14
Data for comparison of our study population was found
in the younger subgroups of larger studies. In general, one
should always consider the differences between the study
cohorts, because of their influence on the outcome. Sur-
vival will be lowered by various comorbidities, the use
of combined procedures, and an impaired left ventricular
function. Furthermore, isolated insufficiency as cause of
AVR is associated with inferior early- and long-term sur-
vival, especially in younger age patients.15 The age of
the study cohort is of particular importance, because it in-
fluences the survival of the study cohort and the durability
of the prostheses and because freedom from reoperation
decreases with the younger age of patients.5 These facts
must be considered, because our study cohort had a high
fraction of patients with impaired left ventricular function
(39%) and isolated insufficiency as the surgical indication
(42.5%), and in 31.7% of the cases, additional procedures
were done.
A review of selected studies is presented in Table 3,
which clarifies the comparable survival throughout the dif-
ferent valve types, if one remembers the differences in the
study cohorts (especially the difference in the mean age).
For the comparison of bioprosthetic AVR and mechanical
AVR, comparable survival was also approved by several
randomized trials.5,16 However, Ruel and colleagues16
showed a survival advantage of about 13% at 20 years of
follow-up for bioprostheses compared with mechanical
AVR. Freedom from death, attributable to ischemic or hem-
orrhagic stroke after 20 years, was 14% greater for those
with tissue AVR than those with mechanical AVR.16 Addi-
tionally, the requirement for lifelong anticoagulation treat-
ment17 results in an elevated risk of bleeding18 and
thromboembolic complications.15
The comparison with the age- and gender-matched gen-
eral German population was done by creating a comparable
cohort inside our study population. To obtain such a cohort,ery c January 2014
FIGURE 2. Freedom from reoperation of total study population and stratified by diameter of Edwards Prima Plus (EPP).
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EPP and normal left ventricular function. The patients
with isolated aortic valve regurgitation as the surgicalTABLE 3. Long-term outcome of several comparable studies
Investigator Prosthesis type P
Present study EPP
Welke et al,19 2011 Stented bioprosthesis (Carpentier-Edwards) 50
McClure et al,22 2010 Stented bioprosthesis (Carpentier-Edwards) 6
Valfre et al,23 2010 Hancock II stented bioprosthesis 6
Ruel et al,16 2007 Stented bioprosthesis
Mechanical prosthesis
Rizzoli et al,24 2006 Hancock II stented bioprosthesis 6
Oxenham et al,18 2003 Mechanical prosthesis (Bjork-Shiley)
Stented bioprosthesis
Hammermeister et al,5,25
2000, 1993
Mechanical prosthesis
Stented bioprosthesis
Chambers et al,20 1997 Pulmonary autograft procedure (Ross
procedure)
EPP, Edwards Prima Plus; NR, not reported.
The Journal of Thoracic and Caindication were excluded because of the previously men-
tioned impaired survival.15 Figure 1 shows the slightly
lower survival of this selected cohort than that of the generalatient age (y) Survival (%) Freedom from reoperation (%)
53.1 10 y: 71.8%
15 y: 48.8%
10 y: 85.6%
14 y: 65.2%
Median: 14.5 y
-64 (mean NR) 10 y: 72%
15 y: 57%
10 y: 68%
15 y: 41%
5 y (mean NR) 10 y: 71.5%
15 y: 43.7%
NR for age 65 y
0 y (mean NR) 10 y: 69.4%
15 y: 60.0%
10 y: 87.4%
15 y: 62.6%
47.6 y 10 y: 80.0%
15 y: 75.0%
20 y: 65.5%
20 y: 11.4%
Median: 10.2 y
47.6 y 10 y: 80.0%
15 y: 70.0%
20 y: 52.3%
20 y: 73.0%
Median:>35 y
0 y (mean NR) NR for age 60 y 15 y: 55.8%
53.9 y 10 y: 64.0%
20 y: 28.4%
10 y: 95.8%
20 y: 92.6%
53.9 y 10 y: 65.7%
20 y: 31.1%
10 y: 88.7%
20 y: 43.8%
59 y 11 y: 47%
15 y: 34%
11 y: 93%
15 y: 90%
59 y 11 y: 41%
15 y: 21%
11 y: 84%
15 y: 71%
32 y 20 y: 61% 20 y: autograft, 75%
20 y: homograft, 80%
rdiovascular Surgery c Volume 147, Number 1 267
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rates for younger patients after AVR have been greater
than those in the general population, but that older patients
reach the same survival rate as the general population,19
these are satisfactory results.
In terms of the durability of bioprosthetic AVR, the free-
dom from reoperation rates in the different studieswere com-
parable (Table 3). In summary, EPP showed better freedom
from reoperation rates than did various other studied valves,
especially remembering the low mean age of our study co-
hort with its effect on lowering durability.5 In the present
study, age did not lower the freedom from reoperation
(Table 2), another indication of the superior durability of
EPP. Mechanical AVR showed superior durability; however,
the low reoperation rates for mechanical AVR must be
weighed against the disadvantages. The pulmonary autograft
procedure shows high freedom from autograft or pulmonary
position homograft replacement20 but is still controversial
regarding late autograft competence and the consequences
of creating pulmonary valve disease. Additionally, it was pri-
marily used for patients far younger than those in our cohort
and lacks comparable long-term results.20
In particular, patients with impaired left ventricular func-
tion should be considered. The improved hemodynamic be-
havior of SAVs has been reported to lead to an improvement
in left ventricular function10 and a resulting survival bene-
fit.21 In general, patients with impaired left ventricular func-
tion tend to have a worse outcome. This results in
a reduction of patients in need of reoperation. Because of
the high freedom from reoperation observed in the present
study, the implantation of EPP can be especially recommen-
ded for these patients.Study Limitations
The major limitation was the retrospective nature of our
study, which could have led to an underestimation of the
complication rates owing to patient misinterpretation or re-
call bias. Despite this limitation, we must remember that
a controlled randomized trial of young patients involving
stentless, stented, and mechanical AVR is not possible or,
at least, would very difficult to perform.CONCLUSIONS
After AVR with EPP in younger patients (which, to our
knowledge, has not yet been studied in larger cohorts), we
found long-term results in survival, comparable to those
for stented biologic AVR and mechanical AVR. Freedom
from reoperation after implantation of EPP was at least
comparable to that after stented AVR but was worse than
that after mechanical prostheses.
We have concluded that AVR with EPP is also an accept-
able option for the treatment of aortic valve disease in youn-
ger patients.268 The Journal of Thoracic and Cardiovascular SurgReferences
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